HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oscar Cirioni Selected Research

antimicrobial peptide IB-367 (iseganan)

5/2014In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria.
10/2013IB-367 pre-treatment improves the in vivo efficacy of teicoplanin and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus.
4/2009Antimicrobial peptides (Temporin A and Iseganan IB-367): effect on the cysticerci of Taenia crassiceps.
11/2007Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection.
1/2006In vitro activity of synthetic antimicrobial peptides against Candida.
11/2003Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Oscar Cirioni Research Topics

Disease

58Infections
03/2022 - 09/2002
30Sepsis (Septicemia)
11/2021 - 07/2002
14Wounds and Injuries (Trauma)
11/2021 - 01/2008
14Staphylococcal Infections
01/2016 - 10/2003
14Septic Shock (Toxic Shock Syndrome)
10/2008 - 01/2002
9Wound Infection (Wound Infections)
10/2021 - 01/2008
7Bacteremia
11/2007 - 02/2005
5Peritonitis
01/2017 - 11/2002
5Body Weight (Weight, Body)
09/2008 - 01/2002
4Infertility (Sterility)
12/2013 - 07/2008
3Surgical Wound
12/2019 - 04/2008
3Burns
01/2017 - 01/2012
3Pseudomonas Infections
12/2008 - 12/2007
3Catheter-Related Infections
09/2006 - 10/2005
2Pneumonia (Pneumonitis)
02/2022 - 03/2005
2Hypersensitivity (Allergy)
06/2021 - 04/2021
2COVID-19
06/2021 - 04/2021
2Surgical Wound Infection
01/2018 - 11/2005
2Obstructive Jaundice (Cholestatic Jaundice)
11/2006 - 09/2006
2Shock
02/2005 - 02/2004
2Necrosis
09/2004 - 01/2002
1Urinary Tract Infections (Urinary Tract Infection)
02/2022
1Staphylococcal Skin Infections
11/2021

Drug/Important Bio-Agent (IBA)

36Anti-Bacterial Agents (Antibiotics)IBA
11/2021 - 02/2003
16Peptides (Polypeptides)IBA
01/2017 - 01/2002
10EndotoxinsIBA
11/2006 - 01/2002
9Antimicrobial PeptidesIBA
01/2018 - 12/2004
8VancomycinFDA LinkGeneric
01/2020 - 10/2003
8Tigecycline (Tygacil)FDA Link
01/2018 - 07/2010
8ImipenemFDA Link
01/2017 - 07/2002
8RNAIII inhibiting peptideIBA
06/2008 - 08/2003
8temporinIBA
04/2008 - 11/2002
7CathelicidinsIBA
10/2021 - 01/2004
7pexigananIBA
01/2018 - 09/2004
7DaptomycinFDA Link
12/2017 - 09/2011
7Polyethylene Terephthalates (Polyethylene Terephthalate)IBA
08/2013 - 09/2002
6Rifampin (Rifampicin)FDA LinkGeneric
01/2018 - 06/2006
6TeicoplaninIBA
12/2016 - 12/2007
6antimicrobial peptide IB-367 (iseganan)IBA
05/2014 - 11/2003
6SolutionsIBA
07/2012 - 01/2002
6LipopolysaccharidesIBA
01/2008 - 06/2003
6GlycopeptidesIBA
04/2007 - 09/2002
5Anti-Infective Agents (Microbicides)IBA
01/2020 - 12/2004
5Colistin (Coly-Mycin)FDA Link
12/2016 - 11/2005
5Linezolid (Zyvox)FDA Link
11/2007 - 10/2003
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2006 - 01/2002
4CollagenIBA
10/2021 - 09/2002
4Methicillin (Metin)FDA Link
01/2016 - 11/2002
4Pharmaceutical PreparationsIBA
01/2016 - 07/2004
4AgarIBA
08/2013 - 08/2003
4Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric
12/2011 - 12/2007
4BMAP-28IBA
07/2008 - 12/2004
4PiperacillinFDA LinkGeneric
07/2006 - 01/2002
4MagaininsIBA
11/2005 - 01/2002
3dalbavancinIBA
09/2021 - 01/2020
3Clarithromycin (Biaxin)FDA LinkGeneric
06/2011 - 11/2005
3Tachypleus tridentatus tachyplesin peptideIBA
12/2008 - 12/2007
3Sodium ChlorideFDA LinkGeneric
07/2004 - 01/2002
2AztreonamFDA LinkGeneric
03/2022 - 11/2021
2VaccinesIBA
06/2021 - 04/2021
2OmigananIBA
01/2017 - 01/2006
2CopperIBA
01/2017 - 01/2012
2Raltegravir PotassiumFDA Link
01/2015 - 01/2013
2RNA (Ribonucleic Acid)IBA
01/2015 - 07/2004
2Matrix Metalloproteinase 9 (Gelatinase B)IBA
06/2013 - 01/2012
2Vitamin EFDA LinkGeneric
12/2011 - 09/2011
2Amikacin (A.M.K)FDA LinkGeneric
06/2011 - 11/2005
2thanatinIBA
04/2011 - 07/2010
2buforin IIIBA
04/2009 - 07/2002
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
10/2008 - 01/2008
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2008 - 01/2008
2distinctinIBA
09/2008 - 04/2007
2indolicidinIBA
01/2008 - 07/2002
2LipopeptidesIBA
06/2007 - 01/2007
2ExotoxinsIBA
09/2006 - 02/2005
2Proteins (Proteins, Gene)FDA Link
05/2006 - 08/2003
2AmidesIBA
11/2005 - 01/2002
2Ciprofloxacin (Cipro)FDA LinkGeneric
11/2005 - 10/2005
2quinupristin-dalfopristin (Synercid)FDA Link
10/2005 - 09/2002
2HistatinsIBA
03/2005 - 07/2004
2Polymyxin B (Aerosporin)FDA LinkGeneric
07/2004 - 01/2002
2Levofloxacin (Levaquin)FDA Link
10/2003 - 01/2002
1ceftazidime drug combination avibactamIBA
02/2022
1CephalosporinaseIBA
02/2022
1Virulence Factors (Pathogenicity Factors)IBA
11/2021
1BerberineIBA
11/2021
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2021
1LipoglycopeptidesIBA
09/2021
1homocysteine-thiolactone-nicotinamide (ST 22)IBA
08/2021

Therapy/Procedure

13Punctures
01/2017 - 07/2002
13Ligation
01/2017 - 07/2002
11Therapeutics
11/2021 - 01/2007
11Intraperitoneal Injections
01/2016 - 01/2002
6Central Venous Catheters
11/2007 - 10/2005
5Operative Surgical Procedures
12/2013 - 07/2008
5Prostheses and Implants (Prosthesis)
08/2013 - 08/2003
5Stents
07/2012 - 12/2007
4Antibiotic Prophylaxis
07/2012 - 06/2006
1Artificial Respiration (Mechanical Ventilation)
02/2022
1Organ Transplantation
02/2022